NYtimes writes of this questionable blockbuster Gilead’s Covid-19 Drug Is Mediocre. It Will Be a Blockbuster Anyway.
EU made a deal for 30,000 tretaments paying 63 mio € or €2100 per patient treated, this was back in July https://www.europarl.europa.eu/doceo/document/E-9-2020-004458_EN.html
Apparently the EU made another deal with Gilead in October just one week before the Solidarity trial results came out, speaking of bricks in the box, the agreement lock a bricks price of about $2400 per patient treated (up to 500,000 pat, but no EU country is under obligation to buy https://www.sciencemag.org/news/2020/10/very-very-bad-look-remdesivir-first-fda-approved-covid-19-drug
Other price points I found on Google:
In US after FDA authorisation the government will buy at prices between 2340 and 3200 USdollars https://www.biopharmadive.com/news/gilead-remdesivir-veklury-supply-us-distribution/586266/
Remdevisir was licensed if I well remeber in Bangladesh and maybe also India so there is another price point, this time the name is Cipremi and prices about €65 per vial (that would make 300 per course) https://health.economictimes.indiatimes.com/news/pharma/cipla-to-price-remdesivir-version-for-covid-19-under-5000-rupees/76531644